Major Depressive Disorder
CNS 3 original drugs 3
Novel Drugs
24
Reformulations
0
Active Trials
23
Drug Targets
Market Leaders
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q3 2026
Dextromethorphan and Bupropion Sustained-Release Tablets
CSPC Ouyi Pharmaceutical Co., Ltd.
Estimated · stale NCT06958692
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 10 mechanisms across 32 industry trials with a known mechanism of action.
Atypical Antipsychotic
17 trials 7 sponsors
DAT
4 trials 1 sponsor
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
3 trials 2 sponsors
Melatonin Receptor Agonist
2 trials 2 sponsors
Dopamine transporter/Norepinephrine transporter
1 trials 1 sponsor
NET/SERT
1 trials 1 sponsor
Progestin Antagonist
1 trials 1 sponsor
Benzodiazepine
1 trials 1 sponsor
Acetylcholine Release Inhibitor
1 trials 1 sponsor
SERT
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
638 industry-sponsored trials across 169 sponsors
Showing 60 of 60 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Neurocrine Biosciences | Valbenazine | — | RECRUITING | 2027-01 | NCT07105111 |
| Janssen Korea, Ltd., Korea | Esketamine 56 mg | — | RECRUITING | 2027-06-25 | NCT07053345 |
| Axsome Therapeutics, Inc. | AXS-05 | — | RECRUITING | 2026-03 | NCT06223880 |
| Luye Pharma Group Ltd. | Toludesvenlafaxine Hydrochloride Sustained-release Tablets | — | NOT YET RECRUITING | 2027-02-28 | NCT06426485 |
| Bausch Health Americas, Inc. | bupropion hydrobromide | Dopamine transporter/Norepinephrine transporter | NOT YET RECRUITING | 2029-07 | NCT02129751 |
| Neurocrine Biosciences | Valbenazine | — | COMPLETED | 2024-12-27 | NCT05859698 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2024-07-22 | NCT04829318 |
| Johnson & Johnson | Esketamine 56 mg | — | COMPLETED | 2024-01-31 | NCT04599855 |
| AbbVie | — | — | COMPLETED | 2022-12-06 | NCT04390581 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Fremanezumab | — | COMPLETED | 2022-08-31 | NCT04041284 |
| Supernus Pharmaceuticals, Inc. | ZULRESSO® | — | COMPLETED | 2022-07-14 | NCT05059600 |
| H. Lundbeck A/S | Vortioxetine | — | COMPLETED | 2022-07-06 | NCT04294654 |
| Field Trip Health | — | — | COMPLETED | 2022-06-16 | NCT05604794 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Brexpiprazole | Atypical Antipsychotic [EPC] | COMPLETED | 2022-05-27 | NCT04830215 |
| H. Lundbeck A/S | Vortioxetine | — | COMPLETED | 2022-02-11 | NCT04288895 |
| H. Lundbeck A/S | Vortioxetine | — | COMPLETED | 2022-01-06 | NCT04448431 |
| Brainsway | — | — | COMPLETED | 2020-07-01 | NCT04679753 |
| H. Lundbeck A/S | Vortioxetine | — | COMPLETED | 2020-02-21 | NCT03835715 |
| Takeda | Vortioxetine | — | COMPLETED | 2019-03-01 | NCT02371980 |
| The Taub Group | Scopolamine and naltrexone | — | COMPLETED | 2018-11-20 | NCT03386448 |
| Assurex Health Inc. | — | — | COMPLETED | 2018-11 | NCT02466477 |
| Takeda | Vortioxetine | — | COMPLETED | 2018-02-06 | NCT02972632 |
| Takeda | Ramelteon | Melatonin Receptor Agonist [EPC] | COMPLETED | 2018-01-31 | NCT02669082 |
| Lundbeck Canada Inc. | vortioxetine | — | COMPLETED | 2017-07-06 | NCT02332954 |
| AbbVie | — | — | COMPLETED | 2016-12-14 | NCT02980783 |
| Forest Laboratories | Levomilnacipran ER | — | COMPLETED | 2016-09-16 | NCT02288325 |
| Xian-Janssen Pharmaceutical Ltd. | Escitalopram | — | COMPLETED | 2015-05 | NCT01870843 |
| Forest Laboratories | Vilazodone | — | COMPLETED | 2014-10 | NCT01573598 |
| Forest Laboratories | Vilazodone | — | COMPLETED | 2013-06 | NCT01473381 |
| Taiwan Otsuka Pharm. Co., Ltd | Aripiprazole | Atypical Antipsychotic [EPC] | COMPLETED | 2013-05 | NCT01429831 |
| Eli Lilly | Duloxetine | — | COMPLETED | 2013-03 | NCT01051466 |
| Forest Laboratories | Vilazodone | — | COMPLETED | 2013-02 | NCT01473394 |
| Forest Laboratories | Escitalopram | — | COMPLETED | 2013-01 | NCT01198795 |
| Pfizer | desvenlafaxine succinate sustained-release 50 mg/day | — | COMPLETED | 2012-07 | NCT01432457 |
| Pfizer | varenicline | — | COMPLETED | 2012-06 | NCT01078298 |
| Xian-Janssen Pharmaceutical Ltd. | Escitalopram | — | COMPLETED | 2012-02 | NCT01814085 |
| Pfizer | desvenlafaxine succinate sustained-release | — | COMPLETED | 2011-06 | NCT01121484 |
| Xian-Janssen Pharmaceutical Ltd. | Escitalopram | — | COMPLETED | 2011-05-31 | NCT01814098 |
| Eli Lilly | Duloxetine | — | COMPLETED | 2011-03 | NCT01070329 |
| Eli Lilly | Duloxetine hydrochloride | — | COMPLETED | 2011-02 | NCT00960986 |
| Pfizer | Desvenlafaxine Succinate Sustained-Release Formulation 50 mg | — | COMPLETED | 2011-02 | NCT01056289 |
| Eli Lilly | Duloxetine | — | COMPLETED | 2010-12 | NCT00985504 |
| Eli Lilly | Duloxetine | — | COMPLETED | 2010-10 | NCT01000805 |
| Pfizer | Desvenlafaxine Succinate Sustained Release | — | COMPLETED | 2010-08 | NCT00952653 |
| Nang Kuang Pharmaceutical Co., Ltd. | Smilon® | — | COMPLETED | 2010-08 | NCT01119924 |
| Boehringer Ingelheim | Duloxetine 60 mg QD | — | COMPLETED | 2010-06 | NCT00844194 |
| Eli Lilly | Duloxetine Hydrochloride | — | COMPLETED | 2010-02 | NCT00810069 |
| Wyeth is now a wholly owned subsidiary of Pfizer | — | — | COMPLETED | 2009-07 | NCT00788944 |
| Eli Lilly | Duloxetine | — | COMPLETED | 2009-07 | NCT00696774 |
| Eli Lilly | duloxetine | — | COMPLETED | 2009-02 | NCT00666757 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Aripiprazole or other oral antipsychotics | — | TERMINATED | 2018-10-17 | NCT03643159 |
| Novartis | Venlafaxine | — | TERMINATED | 2013-09 | NCT01436643 |
| GSK | paroxetine 10mg tablet | — | TERMINATED | 2011-02 | NCT00812812 |
| Rafa Laboratories | hypericum | — | TERMINATED | 2010-11 | NCT00557427 |
| Alto Neuroscience | Sertraline | — | WITHDRAWN | 2023-05-30 | NCT04388202 |
| Alto Neuroscience | Duloxetine | — | WITHDRAWN | 2023-05-30 | NCT04388189 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Brexpiprazole | Atypical Antipsychotic [EPC] | WITHDRAWN | 2023-03-22 | NCT05504486 |
| Sage Therapeutics | Brexanolone | — | WITHDRAWN | 2021-08 | NCT04273191 |
| GSK | Paroxetine CR | — | WITHDRAWN | 2014-09 | NCT01916200 |
| Wyeth is now a wholly owned subsidiary of Pfizer | Effexor XR | NET/SERT | WITHDRAWN | 2011-10 | NCT00878748 |
Showing 100 of 248 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Cybin IRL Limited | CYB003 | — | RECRUITING | 2026-08 | NCT06564818 |
| Xenon Pharmaceuticals Inc. | Azetukalner | — | RECRUITING | 2026-08 | NCT06775379 |
| Intra-Cellular Therapies, Inc. | Lumateperone | — | RECRUITING | 2026-09 | NCT05850689 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | Dextromethorphan and Bupropion Sustained-Release Tablets | — | RECRUITING | 2026-09-30 | NCT06958692 |
| Johnson & Johnson | Seltorexant | — | RECRUITING | 2026-12-30 | NCT06559306 |
| AbbVie | Cariprazine | — | RECRUITING | 2027-03 | NCT04777357 |
| Cybin IRL Limited | CYB003 | — | RECRUITING | 2027-03-18 | NCT06793397 |
| Xenon Pharmaceuticals Inc. | Azetukalner | — | RECRUITING | 2027-05 | NCT07076407 |
| Neumora Therapeutics, Inc. | NMRA-335140 | — | RECRUITING | 2027-06 | NCT06029439 |
| Sunshine Lake Pharma Co., Ltd. | Mitizodone Phosphate tablets | — | RECRUITING | 2027-07 | NCT04984512 |
| Neurocrine Biosciences | NBI-1065845 | — | RECRUITING | 2027-07 | NCT06963021 |
| Neurocrine Biosciences | NBI-1065845 | — | RECRUITING | 2027-07 | NCT06911112 |
| Neurocrine Biosciences | NBI-1065845 | — | RECRUITING | 2027-07 | NCT06786624 |
| Definium Therapeutics US, Inc. | DT120 | — | RECRUITING | 2027-09 | NCT07592689 |
| Eli Lilly | Brenipatide | — | RECRUITING | 2028-02 | NCT07412756 |
| Vanda Pharmaceuticals | Milsaperidone | — | RECRUITING | 2028-03 | NCT06830044 |
| Neurocrine Biosciences | NBI-1065845 | — | RECRUITING | 2028-07 | NCT07196501 |
| Johnson & Johnson | Seltorexant | — | RECRUITING | 2028-08-24 | NCT07573176 |
| Axsome Therapeutics, Inc. | Solriamfetol 150 MG | — | RECRUITING | 2028-12 | NCT07484217 |
| Neurocrine Biosciences | NBI-1065845 | — | RECRUITING | 2029-05 | NCT06966401 |
| Takeda | Vortioxetine tablets | — | RECRUITING | 2029-09-30 | NCT07204314 |
| Johnson & Johnson | Esketamine | — | RECRUITING | 2031-04-09 | NCT07227454 |
| Korea Otsuka Pharmaceutical Co., Ltd. | Abilify 2, 5, 10, 15mg (Tablet) | — | RECRUITING | 2025-11 | NCT03423680 |
| Definium Therapeutics US, Inc. | MM120 (LSD D-Tartrate) | — | ACTIVE NOT RECRUITING | 2026-11 | NCT06941844 |
| Neumora Therapeutics, Inc. | NMRA-335140 | — | ACTIVE NOT RECRUITING | 2026-05 | NCT06058039 |
| Neumora Therapeutics, Inc. | NMRA-335140 | — | ACTIVE NOT RECRUITING | 2026-05 | NCT06058013 |
| COMPASS Pathways | Psilocybin | — | ACTIVE NOT RECRUITING | 2026-02 | NCT05711940 |
| COMPASS Pathways | Psilocybin | — | ACTIVE NOT RECRUITING | 2025-05-28 | NCT05624268 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Ammoxetine | — | NOT YET RECRUITING | 2026-06-30 | NCT06827431 |
| Tasly Pharmaceutical Group Co., Ltd | JS1-1-01 low-dose group | — | NOT YET RECRUITING | 2026-12-31 | NCT07485595 |
| NeuroRx, Inc. | NRX-101 | — | NOT YET RECRUITING | 2026-12-31 | NCT07227103 |
| Lipocine Inc. | LPCN 1154A | — | COMPLETED | 2026-01-16 | NCT06979544 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | Levomilnacipran Hydrochloride Extended-Release Capsules | — | COMPLETED | 2025-06-13 | NCT07253207 |
| Axsome Therapeutics, Inc. | Solriamfetol 300 mg | — | COMPLETED | 2024-12-31 | NCT06360419 |
| Neumora Therapeutics, Inc. | NMRA-335140 | — | COMPLETED | 2024-12-03 | NCT06029426 |
| Johnson & Johnson | Aticaprant | — | COMPLETED | 2024-11-08 | NCT05550532 |
| Intra-Cellular Therapies, Inc. | Lumateperone | — | COMPLETED | 2024-10-14 | NCT05061719 |
| Johnson & Johnson | Aticaprant | — | COMPLETED | 2024-09-18 | NCT05455684 |
| Intra-Cellular Therapies, Inc. | Lumateperone | — | COMPLETED | 2024-04-12 | NCT05061706 |
| Intra-Cellular Therapies, Inc. | Lumateperone | — | COMPLETED | 2024-02-22 | NCT04985942 |
| Johnson & Johnson | Seltorexant | — | COMPLETED | 2023-10-03 | NCT04513912 |
| Relmada Therapeutics, Inc. | REL-1017 | — | COMPLETED | 2023-07-27 | NCT04855760 |
| Biogen | SAGE-217 | — | COMPLETED | 2023-06-22 | NCT03864614 |
| Janssen-Cilag, S.A. | Esketamine | — | COMPLETED | 2023-06-16 | NCT04476446 |
| Johnson & Johnson | Seltorexant | — | COMPLETED | 2023-04-25 | NCT04533529 |
| Johnson & Johnson | Esketamine Nasal Spray | — | COMPLETED | 2022-12-30 | NCT02782104 |
| Intra-Cellular Therapies, Inc. | Lumateperone | — | COMPLETED | 2022-11-30 | NCT04285515 |
| Relmada Therapeutics, Inc. | REL-1017 | — | COMPLETED | 2022-11-01 | NCT04688164 |
| Relmada Therapeutics, Inc. | REL-1017 | — | COMPLETED | 2022-09-13 | NCT05081167 |
| AbbVie | Cariprazine | — | COMPLETED | 2022-09-05 | NCT03573297 |
| Mochida Pharmaceutical Company, Ltd. | Desvenlafaxine 100 mg | — | COMPLETED | 2022-07-21 | NCT04345471 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Brexpiprazole | Atypical Antipsychotic [EPC] | COMPLETED | 2022-07-08 | NCT03538691 |
| Otsuka Pharmaceutical Co., Ltd. | Brexpiprazole | Atypical Antipsychotic [EPC] | COMPLETED | 2022-06-06 | NCT03697603 |
| Praxis Precision Medicines | PRAX-114 | — | COMPLETED | 2022-05-05 | NCT04832425 |
| Biogen | SAGE-217 | — | COMPLETED | 2022-03-15 | NCT04442503 |
| H. Lundbeck A/S | Vortioxetine 10 mg/day | — | COMPLETED | 2022-01-21 | NCT02709655 |
| Janssen-Cilag International NV | Esketamine 28 mg | — | COMPLETED | 2022-01-20 | NCT04338321 |
| Biogen | SAGE-217 | — | COMPLETED | 2021-10-25 | NCT04476030 |
| AbbVie | Cariprazine | — | COMPLETED | 2021-09-30 | NCT03738215 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Duloxetine Hydrochloride Enteric-coated Capsule | — | COMPLETED | 2021-09-22 | NCT04364997 |
| AbbVie | Cariprazine | — | COMPLETED | 2021-09-06 | NCT03739203 |
| Johnson & Johnson | Esketamine 56 mg | — | COMPLETED | 2021-04-13 | NCT03434041 |
| Biogen | SAGE-217 | — | COMPLETED | 2021-03-26 | NCT04442490 |
| Otsuka Pharmaceutical Co., Ltd. | Brexpiprazole | Atypical Antipsychotic [EPC] | COMPLETED | 2021-03-17 | NCT03737474 |
| AbbVie | Levomilnacipran ER | — | COMPLETED | 2021-03-01 | NCT03569475 |
| Supernus Pharmaceuticals, Inc. | Brexanolone | — | COMPLETED | 2021-01-08 | NCT03665038 |
| Luye Pharma Group Ltd. | LY03005 extended-release tablet | — | COMPLETED | 2020-12-24 | NCT04853407 |
| Axsome Therapeutics, Inc. | AXS-05 (dextromethorphan and bupropion) oral tablets | — | COMPLETED | 2020-10-23 | NCT04039022 |
| ACADIA Pharmaceuticals Inc. | Pimavanserin | — | COMPLETED | 2020-04-30 | NCT03968159 |
| H. Lundbeck A/S | Vortioxetine | — | COMPLETED | 2020-04-16 | NCT03108625 |
| Axsome Therapeutics, Inc. | AXS-05 | — | COMPLETED | 2020-03-20 | NCT02741791 |
| Alkermes, Inc. | ALKS 5461 | — | COMPLETED | 2020-02-26 | NCT03188185 |
| Axsome Therapeutics, Inc. | AXS-05 | — | COMPLETED | 2019-11-26 | NCT04019704 |
| Shionogi | Duloxetine Hydrochloride | — | COMPLETED | 2019-11-08 | NCT03315793 |
| Biogen | SAGE-217 | — | COMPLETED | 2019-09-24 | NCT03672175 |
| Forest Laboratories | Levomilnacipran | — | COMPLETED | 2019-08-19 | NCT02431806 |
| H. Lundbeck A/S | Vortioxetine 10 mg/day | — | COMPLETED | 2019-07-02 | NCT02709746 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2019-04-11 | NCT03097133 |
| Naurex, Inc, an affiliate of Allergan plc | Rapastinel | — | COMPLETED | 2019-02-22 | NCT02951988 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2018-12-18 | NCT03039192 |
| Naurex, Inc, an affiliate of Allergan plc | Rapastinel | — | COMPLETED | 2018-12-12 | NCT02943564 |
| Naurex, Inc, an affiliate of Allergan plc | Rapastinel | — | COMPLETED | 2018-12-06 | NCT03002077 |
| Biogen | SAGE-217 15/20 mg Oral Solution | — | COMPLETED | 2018-11-15 | NCT02978326 |
| Naurex, Inc, an affiliate of Allergan plc | Rapastinel | — | COMPLETED | 2018-10-26 | NCT02943577 |
| Naurex, Inc, an affiliate of Allergan plc | Rapastinel | — | COMPLETED | 2018-09-21 | NCT02932943 |
| Forest Laboratories | Vilazodone | — | COMPLETED | 2018-09-11 | NCT02372799 |
| Forest Laboratories | Vilazodone | — | COMPLETED | 2018-07-23 | NCT02436239 |
| Takeda | Vortioxetine | — | COMPLETED | 2018-03-16 | NCT02389816 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2018-02-20 | NCT02417064 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2018-02-15 | NCT02493868 |
| Forest Laboratories | Cariprazine | — | COMPLETED | 2018-01-18 | NCT02670538 |
| Alkermes, Inc. | ALKS 5461 | — | COMPLETED | 2017-11-20 | NCT02141399 |
| Johnson & Johnson | Esketamine (Intranasal Spray) | — | COMPLETED | 2017-10-28 | NCT02497287 |
| Supernus Pharmaceuticals, Inc. | SAGE-547 60 μg/kg/h | — | COMPLETED | 2017-09-24 | NCT02942004 |
| Supernus Pharmaceuticals, Inc. | SAGE-547 90 μg/kg/h | — | COMPLETED | 2017-09-17 | NCT02942017 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2017-08-10 | NCT02422186 |
| Forest Laboratories | Cariprazine | — | COMPLETED | 2017-07-19 | NCT02670551 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2017-06-01 | NCT02418585 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | OPC-34712 | — | COMPLETED | 2017-04-18 | NCT01360866 |
| Ybrain Inc. | — | — | COMPLETED | 2016-12 | NCT02657980 |
Showing 100 of 204 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Sichuan Purity Pharmaceutical Technology Co., Ltd. | Low Dose PRT042 nasal spray | — | RECRUITING | 2026-06 | NCT07193901 |
| Autobahn Therapeutics, Inc. | ABX-002 | — | RECRUITING | 2026-06 | NCT06633016 |
| Johnson & Johnson | JNJ-89495120 | — | RECRUITING | 2026-06-26 | NCT06785012 |
| atai Therapeutics, Inc. | VLS-01-203 BU | — | RECRUITING | 2026-08-01 | NCT06524830 |
| Gilgamesh Pharmaceuticals | GM-2505 | — | RECRUITING | 2026-10 | NCT06236880 |
| Beckley Psytech Limited | BPL-003 | — | RECRUITING | 2026-11 | NCT05660642 |
| Alto Neuroscience | ALTO-300 | — | RECRUITING | 2026-12 | NCT05922878 |
| Mapi Pharma Ltd. | Cariprazine Depot | — | RECRUITING | 2026-12-31 | NCT07185815 |
| Supernus Pharmaceuticals, Inc. | SPN-821 2400 mg | — | RECRUITING | 2026-12-31 | NCT07226661 |
| Seaport Therapeutics | SPT-300 | — | RECRUITING | 2027-03 | NCT07065240 |
| ACADIA Pharmaceuticals Inc. | ACP-211 | — | RECRUITING | 2027-08 | NCT07284667 |
| Draig Therapeutics Ltd | DT-101 | — | RECRUITING | 2027-08 | NCT07300969 |
| AbbVie | Icalcaprant | — | RECRUITING | 2027-09 | NCT07276997 |
| Syndeio Biosciences, Inc | Zelquistinel | — | RECRUITING | 2027-09 | NCT06547489 |
| Alto Neuroscience | ALTO-207 | — | RECRUITING | 2027-11 | NCT07553637 |
| Syndeio Biosciences, Inc | Zelquistinel | — | RECRUITING | 2028-03-30 | NCT07115329 |
| Hangzhou PhecdaMed Co., Ltd. | TJ0113 | — | RECRUITING | 2026-05-25 | NCT07018245 |
| Autobahn Therapeutics, Inc. | ABX-002 | — | RECRUITING | 2026-02-27 | NCT06869187 |
| Sirtsei Pharmaceuticals, Inc. | SP-624 | — | ACTIVE NOT RECRUITING | 2026-07-15 | NCT06254612 |
| Ono Pharmaceutical Co., Ltd. | ONO-1110 | — | ACTIVE NOT RECRUITING | 2026-08-31 | NCT06792136 |
| Chase Therapeutics Corporation | CTC-501 | — | ACTIVE NOT RECRUITING | 2025-12-30 | NCT03642964 |
| Eleusis Therapeutics | ELE-101 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT05434156 |
| Nanjing Minova Pharmaceutical Co., Ltd. | MI078 capsule dose 1 | — | ACTIVE NOT RECRUITING | 2025-10 | NCT06963580 |
| COMPASS Pathways | Psilocybin | — | ACTIVE NOT RECRUITING | 2025-09 | NCT05733546 |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. | KH607 tablet | — | NOT YET RECRUITING | 2027-01 | NCT07096791 |
| Afasci Inc | AFA-281 | — | NOT YET RECRUITING | 2027-06-01 | NCT06710431 |
| Enalare Therapeutics Inc. | ENA-001 | — | NOT YET RECRUITING | 2027-06-15 | NCT06137638 |
| BioLite, Inc. | PDC-1421 Capsule | — | NOT YET RECRUITING | 2028-02-28 | NCT03833206 |
| Soterix Medical | — | — | NOT YET RECRUITING | 2028-06-01 | NCT07287839 |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. | KH607 tablets | — | NOT YET RECRUITING | 2025-12 | NCT07101120 |
| Biohaven Therapeutics Ltd. | BHV-7000 | — | COMPLETED | 2026-03-18 | NCT06423781 |
| Suven Life Sciences Limited | Ropanicant | — | COMPLETED | 2026-02-23 | NCT06836063 |
| Biohaven Therapeutics Ltd. | BHV-7000 | — | COMPLETED | 2025-11-07 | NCT06419608 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | SEP-363856 | — | COMPLETED | 2025-11-06 | NCT05593029 |
| DuKang Pharmaceuticals, Inc. | NORA520 Dose 1 | — | COMPLETED | 2025-09-11 | NCT06285916 |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. | NH102 | — | COMPLETED | 2025-07-30 | NCT06842992 |
| Neurocrine Biosciences | NBI-1070770 | — | COMPLETED | 2025-07-25 | NCT06267846 |
| Clexio Biosciences Ltd. | CLE-100 | — | COMPLETED | 2025-06-06 | NCT06340958 |
| Reunion Neuroscience Inc | RE104 for Injection | — | COMPLETED | 2025-05-22 | NCT06342310 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Centanafadine | — | COMPLETED | 2025-05-16 | NCT05536414 |
| Boehringer Ingelheim | BI 1569912 | — | COMPLETED | 2025-05-02 | NCT06558344 |
| Alto Neuroscience | ALTO-203 25 μg | — | COMPLETED | 2025-04-14 | NCT06391593 |
| Beckley Psytech Limited | BPL-003 | — | COMPLETED | 2025-03-28 | NCT05870540 |
| Gilgamesh Pharmaceuticals | GM-1020 | — | COMPLETED | 2025-03-04 | NCT06309277 |
| Boehringer Ingelheim | BI 1569912 | — | COMPLETED | 2025-02-26 | NCT06280235 |
| Biomind Labs Inc. | Sublingual administration | — | COMPLETED | 2025-02-15 | NCT06812221 |
| Navitor Pharmaceuticals, Inc. | NV-5138 | — | COMPLETED | 2025-01-21 | NCT05066672 |
| Mapreg | MAP4343 | — | COMPLETED | 2024-11-07 | NCT03870776 |
| Tasly Pharmaceutical Group Co., Ltd | JS1-1-01 low-dose group | — | COMPLETED | 2024-10-23 | NCT06259526 |
| GH Research Ireland Limited | GH001 | — | COMPLETED | 2024-10-04 | NCT05800860 |
| Alto Neuroscience | ALTO-100 | — | COMPLETED | 2024-09-05 | NCT05712187 |
| Navitor Pharmaceuticals, Inc. | NV-5138 | — | COMPLETED | 2024-08-18 | NCT06235905 |
| Suven Life Sciences Limited | Ropanicant | — | COMPLETED | 2024-07-19 | NCT06126497 |
| Actinogen Medical | Xanamem™ | — | COMPLETED | 2024-07-01 | NCT05657691 |
| Brii Biosciences Limited | BRII-296 | — | COMPLETED | 2024-03-13 | NCT06057012 |
| Denovo Biopharma LLC | Liafensine | — | COMPLETED | 2024-02-06 | NCT05113771 |
| Boehringer Ingelheim | BI 1358894 | — | COMPLETED | 2024-01-10 | NCT04521478 |
| Neurocrine Biosciences | NBI-1065845 | — | COMPLETED | 2024-01-10 | NCT05203341 |
| Novartis | MIJ821 Subcutaneous Injection 1 mg | — | COMPLETED | 2023-11-28 | NCT05454410 |
| Cybin IRL Limited | CYB003 | — | COMPLETED | 2023-10-16 | NCT05385783 |
| Tonix Pharmaceuticals, Inc. | TNX-601 ER | — | COMPLETED | 2023-09-29 | NCT05686408 |
| Beijing Greatway Pharmaceutical Technology Co.,Ltd. | GW117 Tablets | — | COMPLETED | 2023-09-28 | NCT06796868 |
| Xenon Pharmaceuticals Inc. | XEN1101 10 mg | — | COMPLETED | 2023-09-18 | NCT05376150 |
| Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. | ANC-501 | — | COMPLETED | 2023-08-14 | NCT05439603 |
| Neurocrine Biosciences | NBI-1065846 | — | COMPLETED | 2023-07-07 | NCT05165394 |
| Seelos Therapeutics, Inc. | SLS-002 | — | COMPLETED | 2023-06-17 | NCT04669665 |
| Alto Neuroscience | ALTO-300 oral (PO) tablet | — | COMPLETED | 2023-05-05 | NCT05118750 |
| Alto Neuroscience | ALTO-300 PO Tablet | — | COMPLETED | 2023-04-26 | NCT05157945 |
| Johnson & Johnson | Midazolam | Benzodiazepine [EPC] | COMPLETED | 2023-03-31 | NCT03185819 |
| Alto Neuroscience | ALTO-100 PO Tablet | — | COMPLETED | 2023-01-13 | NCT05419869 |
| Alto Neuroscience | ALTO-100 PO tablet | — | COMPLETED | 2022-12-01 | NCT05117632 |
| Perception Neuroscience | PCN-101 | — | COMPLETED | 2022-11-10 | NCT05414422 |
| Small Pharma Ltd | SPL026 | — | COMPLETED | 2022-10-01 | NCT04673383 |
| Clexio Biosciences Ltd. | CLE-100 | — | COMPLETED | 2022-09-21 | NCT04103892 |
| Praxis Precision Medicines | 10 mg PRAX-114 | — | COMPLETED | 2022-07-15 | NCT04969510 |
| Sirtsei Pharmaceuticals, Inc. | SP-624 | — | COMPLETED | 2022-06-27 | NCT04479852 |
| Neumora Therapeutics, Inc. | NMRA-335140 | — | COMPLETED | 2022-04-08 | NCT04221230 |
| Otsuka Pharmaceutical Co., Ltd. | OPC-64005 20 mg , Once-daily | — | COMPLETED | 2022-02-08 | NCT04244253 |
| GH Research Ireland Limited | 5 Methoxy N,N Dimethyltryptamine | — | COMPLETED | 2021-11-06 | NCT04698603 |
| COMPASS Pathways | Psilocybin | — | COMPLETED | 2021-10-14 | NCT04739865 |
| Johnson & Johnson | JNJ-61393215 | — | COMPLETED | 2021-09-02 | NCT04080752 |
| COMPASS Pathways | Psilocybin | — | COMPLETED | 2021-07-30 | NCT03775200 |
| Axsome Therapeutics, Inc. | AXS-05 | — | COMPLETED | 2021-07-30 | NCT04608396 |
| Johnson & Johnson | JNJ-67953964 | — | COMPLETED | 2020-05-06 | NCT03559192 |
| Sumitomo Pharma America, Inc. | SEP-4199 200 mg | — | COMPLETED | 2020-04-23 | NCT03543410 |
| Novartis | MIJ821 | — | COMPLETED | 2020-03-23 | NCT03756129 |
| Celon Pharma SA | Esketamine DPI - low dose | — | COMPLETED | 2020-03-15 | NCT03965858 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | Hypidone Hydrochloride tablets | — | COMPLETED | 2019-12-18 | NCT03739632 |
| Minerva Neurosciences | MIN-117 5.0 mg | — | COMPLETED | 2019-11-21 | NCT03446846 |
| Syndeio Biosciences, Inc | AGN-241751 | — | COMPLETED | 2019-10-23 | NCT03726658 |
| VistaGen Therapeutics, Inc. | AV-101 | — | COMPLETED | 2019-10-01 | NCT03078322 |
| Janssen Pharmaceutical K.K. | Intranasal esketamine (28 mg) | — | COMPLETED | 2019-08-19 | NCT02918318 |
| H. Lundbeck A/S | Vortioxetine infusion 25 mg | — | COMPLETED | 2019-07-31 | NCT03766867 |
| Relmada Therapeutics, Inc. | REL-1017 | — | COMPLETED | 2019-07-30 | NCT03051256 |
| Syndeio Biosciences, Inc | AGN-241751 | — | COMPLETED | 2019-07-22 | NCT03586427 |
| Marinus Pharmaceuticals | Ganaxolone | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] | COMPLETED | 2019-07-05 | NCT03460756 |
| Avid Radiopharmaceuticals | Flortaucipir F18 | — | COMPLETED | 2019-06-26 | NCT02278367 |
| Johnson & Johnson | JNJ-42847922 | — | COMPLETED | 2019-06-13 | NCT03321526 |
| Marinus Pharmaceuticals | Ganaxolone | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] | COMPLETED | 2019-05-10 | NCT03228394 |
| BioLite, Inc. | PDC-1421 Capsule | — | COMPLETED | 2019-03-12 | NCT02395978 |
Showing 100 of 126 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Enalare Therapeutics Inc. | ENA-001 | — | RECRUITING | 2026-07-30 | NCT06967259 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | MSP-2020 | — | RECRUITING | 2027-01-29 | NCT07329621 |
| Sirtsei Pharmaceuticals, Inc. | SP-624 | — | RECRUITING | 2026-04 | NCT06570369 |
| Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. | SP-101 injection | — | NOT YET RECRUITING | 2026-06-30 | NCT07334249 |
| Corium Innovations, Inc. | Selegiline Transdermal Delivery System | — | NOT YET RECRUITING | 2026-10-07 | NCT07452692 |
| Soterix Medical | Ketamine (0.25 mg/kg) | — | NOT YET RECRUITING | 2027-12-01 | NCT07307768 |
| Nyree Penn | Diprivan (propofol), Astra-Zeneca | — | NOT YET RECRUITING | 2026-05-01 | NCT06644573 |
| Alar Pharmaceuticals Inc. | ALA-3000 | — | COMPLETED | 2025-12-30 | NCT06965569 |
| Engrail Therapeutics INC | ENX-104 | — | COMPLETED | 2025-11-26 | NCT07253324 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | SEP-380135 | — | COMPLETED | 2025-09-12 | NCT07549581 |
| Vigonvita Life Sciences | LV232 40mg | — | COMPLETED | 2025-01-19 | NCT06476509 |
| Biogen | Zuranolone | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] | COMPLETED | 2024-10-18 | NCT05655507 |
| Nanjing Minova Pharmaceutical Co., Ltd. | MI078 | — | COMPLETED | 2024-03-18 | NCT06982651 |
| Brii Biosciences Limited | BRII-297 | — | COMPLETED | 2023-11-21 | NCT05845840 |
| Boehringer Ingelheim | BI 1569912 | — | COMPLETED | 2023-11-16 | NCT04937829 |
| Novartis | MIJ821 | — | COMPLETED | 2023-11-07 | NCT05666687 |
| Small Pharma Ltd | SPL026 | — | COMPLETED | 2023-08-03 | NCT05553691 |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. | NH102 | — | COMPLETED | 2023-04-10 | NCT07324408 |
| Small Pharma Ltd | SPL026 IV | — | COMPLETED | 2023-04-05 | NCT05644093 |
| Syndeio Biosciences, Inc | apimostinel | — | COMPLETED | 2023-04-04 | NCT05597241 |
| Beijing Greatway Pharmaceutical Technology Co.,Ltd. | GW117 ODT | — | COMPLETED | 2023-03-24 | NCT06964711 |
| Johnson & Johnson | Seltorexant Dose 1 | — | COMPLETED | 2023-03-16 | NCT04451187 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-10353 | — | COMPLETED | 2023-03-11 | NCT05195203 |
| Seasons Biotechnology (Taizhou) Co., Ltd. | Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg | — | COMPLETED | 2022-11-25 | NCT05416762 |
| Digestome Therapeutics | DGX-001Dose 1 | — | COMPLETED | 2022-11-06 | NCT05121831 |
| Seasons Biotechnology (Taizhou) Co., Ltd. | Vortioxetine Hemihydrobromide Orally Disintegrating Tablets | — | COMPLETED | 2022-10-27 | NCT05416957 |
| Luye Pharma Group Ltd. | LY03010 156 mg treatment group, deltoid | — | COMPLETED | 2022-09-23 | NCT05321602 |
| Seasons Biotechnology (Taizhou) Co., Ltd. | Vortioxetine Hemihydrobromide Orally Disintegrating Tablets | — | COMPLETED | 2022-09-02 | NCT05417087 |
| Soterix Medical | — | — | COMPLETED | 2022-08-10 | NCT04781127 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-10345 84mg | — | COMPLETED | 2022-04-30 | NCT05196971 |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. | NH102 | — | COMPLETED | 2022-01-11 | NCT05015192 |
| Jiangsu HengRui Medicine Co., Ltd. | HR071603 | — | COMPLETED | 2021-06-01 | NCT04108234 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | Hypidone Hydrochloride tablets | — | COMPLETED | 2021-01-11 | NCT04598607 |
| Sunshine Lake Pharma Co., Ltd. | HEC113995 | — | COMPLETED | 2020-08-12 | NCT04623814 |
| Sunshine Lake Pharma Co., Ltd. | HEC113995 PA•H2O tablets | — | COMPLETED | 2019-12-06 | NCT04591301 |
| BioDelivery Sciences International | Belbuca 300 µg | — | COMPLETED | 2019-10-27 | NCT03996694 |
| Boehringer Ingelheim | BI 1358894 | — | COMPLETED | 2019-08-27 | NCT03854578 |
| Navitor Pharmaceuticals, Inc. | NV-5138 | — | COMPLETED | 2019-06-09 | NCT03606395 |
| Johnson & Johnson | JNJ-42847922 20mg | — | COMPLETED | 2019-04-29 | NCT03374475 |
| Luye Pharma Group Ltd. | LY03005 | — | COMPLETED | 2019-02-16 | NCT03822065 |
| Luye Pharma Group Ltd. | LY03005 | — | COMPLETED | 2018-07-17 | NCT03733574 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Ammoxetine Hydrochloride Enteric-coated Tablets | — | COMPLETED | 2018-07-11 | NCT03456388 |
| Suven Life Sciences Limited | SUVN-911 | — | COMPLETED | 2018-07-10 | NCT03551288 |
| Johnson & Johnson | Esketamine | — | COMPLETED | 2018-06-29 | NCT02919579 |
| Suven Life Sciences Limited | SUVN-911 | — | COMPLETED | 2018-03-07 | NCT03155503 |
| Luye Pharma Group Ltd. | LY03005 | — | COMPLETED | 2017-12-22 | NCT03357796 |
| Syndeio Biosciences, Inc | zelquistinel | — | COMPLETED | 2017-12-21 | NCT04981561 |
| Lee's Pharmaceutical Limited | Trazodone Hydrochloride prolonged-release tablets | — | COMPLETED | 2017-11-30 | NCT02785601 |
| Lee's Pharmaceutical Limited | trazodone hydrochloride prolonged-release tablet | — | COMPLETED | 2017-11-30 | NCT02785614 |
| Neurocrine Biosciences | TAK-653 | — | COMPLETED | 2017-09-11 | NCT02561156 |
| Johnson & Johnson | JNJ-54175446, 600 mg | — | COMPLETED | 2017-06-02 | NCT02902601 |
| Luye Pharma Group Ltd. | LY03005 | — | COMPLETED | 2016-12-28 | NCT02988024 |
| GSK | Bupropion HCl XL tablet 150mg | — | COMPLETED | 2016-06-29 | NCT02698553 |
| Janssen-Cilag International NV | JNJ-42847922 | — | COMPLETED | 2016-01-04 | NCT02476058 |
| Luye Pharma Group Ltd. | LY03005 extended-release tablets 40 mg | — | COMPLETED | 2015-10-31 | NCT03785652 |
| Roche | Basimglurant | — | COMPLETED | 2015-09 | NCT02433093 |
| Naurex, Inc, an affiliate of Allergan plc | NRX-1074 375 mg | — | COMPLETED | 2015-04 | NCT02366364 |
| Luye Pharma Group Ltd. | LY03005 | — | COMPLETED | 2015-03 | NCT02271412 |
| P1vital Products Limited | — | — | COMPLETED | 2015-01 | NCT02800577 |
| Johnson & Johnson | JNJ-42847922 | — | COMPLETED | 2014-12 | NCT02067299 |
| Johnson & Johnson | Aripiprazole, oral formulation | — | COMPLETED | 2014-10 | NCT02087579 |
| Luye Pharma Group Ltd. | LY03005 | — | COMPLETED | 2014-08 | NCT02055300 |
| Neuralstem Inc. | NSI-189 Phosphate | — | COMPLETED | 2014-02 | NCT01520649 |
| H. Lundbeck A/S | Vortioxetine (Lu AA21004) | — | COMPLETED | 2013-09 | NCT01607125 |
| BioLite, Inc. | PDC-1421 | — | COMPLETED | 2013-07 | NCT01774045 |
| MSI Methylation Sciences, Inc. | Ademetionine | — | COMPLETED | 2013-06-08 | NCT04623034 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Brexpiprazole | Atypical Antipsychotic [EPC] | COMPLETED | 2013-05 | NCT01670279 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2012-08 | NCT01460381 |
| Astellas Pharma Inc | FK949E | — | COMPLETED | 2012-06-22 | NCT01919008 |
| Bristol-Myers Squibb | BMS-820836 | — | COMPLETED | 2012-05 | NCT01396252 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-12 | NCT01373931 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-12 | NCT01460407 |
| Pfizer | desvenlafaxine | — | COMPLETED | 2011-12 | NCT01443208 |
| BlackThorn Therapeutics, Inc. | LY2940094 | — | COMPLETED | 2011-11 | NCT01404091 |
| Neuralstem Inc. | NSI-189 Phosphate | — | COMPLETED | 2011-11 | NCT01310881 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-09 | NCT01380691 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-09 | NCT01389752 |
| AbbVie | ABT-436 | — | COMPLETED | 2011-09 | NCT01380704 |
| Astellas Pharma Inc | FK949E | — | COMPLETED | 2011-09 | NCT01903200 |
| BlackThorn Therapeutics, Inc. | LY2940094 | — | COMPLETED | 2011-09 | NCT01263236 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-08 | NCT01389765 |
| Dong Wha Pharmaceutical Co. Ltd. | DWETR10 | — | COMPLETED | 2011-08 | NCT01367080 |
| Astellas Pharma Inc | FK949E | — | COMPLETED | 2011-05 | NCT01924520 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-04 | NCT01241435 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-03 | NCT01263197 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-03 | NCT01263223 |
| Eli Lilly | Clopidogrel | — | COMPLETED | 2011-03 | NCT01263093 |
| AstraZeneca | AZD6765 | — | COMPLETED | 2011-03 | NCT01046630 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-02 | NCT01275144 |
| Eli Lilly | Warfarin | — | COMPLETED | 2011-02 | NCT01263119 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-02 | NCT01266590 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-01 | NCT01263106 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-01 | NCT01243957 |
| Eli Lilly | LY2216684 | — | COMPLETED | 2011-01 | NCT01250873 |
| Pfizer | desvenlafaxine succinate sustained release | — | COMPLETED | 2010-11 | NCT01190514 |
| Bristol-Myers Squibb | BMS-820836 | — | COMPLETED | 2010-11 | NCT00892840 |
| AstraZeneca | — | — | COMPLETED | 2010-10 | NCT01217645 |
| CeNeRx BioPharma Inc. | CX157 | — | COMPLETED | 2010-10 | NCT01633437 |
| GSK | Aripiprazole | Atypical Antipsychotic [EPC] | COMPLETED | 2010-07 | NCT01424449 |
| Novartis | ABP688 | — | COMPLETED | 2010-05 | NCT01528241 |
Novel Drugs by Company (New molecular entities)
Reformulations (24 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
RALDESY
KAMAT
T3 2024
OPIPZA
XIAMEN LP PHARM CO
T3 2024
AUVELITY
AXSOME
T3/4 2022
CAPLYTA
INTRA-CELLULAR
T1 2019
DRIZALMA SPRINKLE
Sun Pharma
T5 2019
VRAYLAR
AbbVie
T1 2015
REXULTI
OTSUKA
EFFICACY 2015
CONTRAVE
NALPROPION
T4 2014
TRINTELLIX
Takeda
T1 2013
FETZIMA
AbbVie
T2 2013
FORFIVO XL
TWI PHARMS
T3 2011
VIIBRYD
AbbVie
T1 2011
APLENZIN
BAUSCH
T2 2008
PRISTIQ
PF PRISM CV
T1 2008
SEROQUEL XR
CHEPLAPHARM
T3 2007
WELLBUTRIN XL
BAUSCH
T3 2003
REMERON SOLTAB
Merck
T3 2001
PAXIL CR
Apotex
T3 1999
CELEXA
AbbVie
T1 1998
EFFEXOR XR
UPJOHN
T3 1997
WELLBUTRIN SR
GSK
T3 1996
REMERON
Merck
T1 1996
PROZAC
Eli Lilly
T1 1987
PARNATE
ADVANZ PHARMA
T1 1961
Drug Targets
Generic Drugs (9 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
DESVENLAFAXINE SUCCINATE
Lupin
LEVOMILNACIPRAN HYDROCHLORIDE
PRINSTON INC
NEFAZODONE HYDROCHLORIDE
Dr. Reddy's
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE
Teva
PAROXETINE
PRINSTON INC
SERTRALINE HYDROCHLORIDE
HERITAGE
TRANYLCYPROMINE SULFATE
NOVITIUM PHARMA
VENLAFAXINE HYDROCHLORIDE
ANCHEN PHARMS
VILAZODONE HYDROCHLORIDE
ALEMBIC
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs